MTOR and acute lymphoblastic leukemia: Alterations in CRLF2, i.e. P2RY8/CRLF2 or IGH@/CRLF2 gene fusions, point mutations (CRLF2F232C) and Janus kinase 2 mutations (JAK2R683G) are frequently associated with CRLF2 overexpression, an expression profile similar to Ph+-ALL (“Ph- or BCR/ABL-like”), and involve aberrant PI3K/mTOR signaling [8-13].